Dear ,
On behalf of Puma Biotechnology, I would like to cordially invite you to participate in the upcoming virtual Alisertib MBC Biomarker Advisory Board.
During this meeting, we will seek your advice and guidance on the biomarker findings and strategy for ALISCA-Breast1 in the context of the rapidly evolving, increasingly biomarker-driven treatment landscape for HR+/HER2- metastatic breast cancer.
In order for us to plan for your attendance, please confirm your participation by clicking the button below to register at your earliest convenience. (you must register using the email address to which this invitation is being sent; otherwise, the system will not allow you to register.)
Please note: All attendees are expected to stay on camera for the entire meeting.
Upon your registration, you will be sent an advisor agreement for signature. For your time and participation in the meeting, we will provide compensation as noted in your advisor agreement.
Please also note that, in accordance with company policy and the PhRMA Code on Interactions with Healthcare Professionals, attendance at this program is limited to healthcare professionals. Additionally, Puma Biotechnology complies with all federal and state transparency reporting requirements concerning payments to healthcare professionals.
If you have any questions, please contact Erin Bowler at erin.bowler@simulations-plus.com.
We thank you for your consideration and hope you will be able to participate.